←Back to Expert Scholars
Translational Medicine / 转化医学Perioperative Therapy, Breast Cancer
Charles Geyer
MD
🏢UPMC Hillman Cancer Center🌐USA
Associate Director for Clinical Investigation
70
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Charles Geyer co-led the KATHERINE trial establishing adjuvant T-DM1 for HER2-positive patients with residual disease after neoadjuvant chemotherapy plus HER2 therapy. His decades of leadership in NSABP/NRG Oncology have shaped adjuvant breast cancer practice. He now works at UPMC Hillman Cancer Center.
Share:
🧪Research Fields 研究领域
KATHERINE trial
T-DM1 adjuvant HER2
NSABP
breast cancer cooperative groups
residual disease
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Charles Geyer 的研究动态
Follow Charles Geyer's research updates
留下邮箱，当我们发布与 Charles Geyer（UPMC Hillman Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment